Peking University is conducting a multicenter, phase 2 clinical trial to compare the efficacy and safety of baricitinib (a Janus kinase inhibitor) plus high-dose dexamethasone (a corticosteroid) to those receiving only high-dose dexamethasone for first-line treatment of adults with primary immune thrombocytopenia (ITP). Participants must have a platelet count less than 30,000 or less than 50,000 with bleeding, and not be receiving any chemotherapy.
China
Actively Recruiting